Clinical Trial Update: A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

A long-term extension study of apremilast in pediatric patients (6-17) with moderate to severe plaque psoriasis has completed in Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• OTEZLA (apremilast)

Snippet

Sponsor: Amgen | Conditions: Psoriasis | Phase 3 | Status: COMPLETED